CSF2 and cancer: ONCO-VEXGM-CSF and all of the Δγ134.5 attenuated oncolytic HSVs gain their cancer specificity, and hence their safety profile, from the fact that most cancer cells are defective in mounting innate immune responses against the viruses with these deletions.